Supplemental File

Table S1. ParentCorps implementation models and impact evidence

	United States (US)	LMICs- Uganda (urban) & Nepal (rural)
School-based Intervention Components	**PD** (3 days + 1:1 individual coaching) + **Family Program** (14 sessions).	**PD** (3-4 days+ a group coaching model to reduce costs and to align with value for working in groups as the "collective culture" + culturally relevant handout to facilitate discussion around EBI-strategies during parent-teacher meetings)
***ParentCorps* Contents**	• **Core EBI strategies included in PD & Family Program**: Draw on social learning theory and cognitive & behavioral principles that target adults' knowledge, skills, and confidence in an effort to reduce or prevent child social, behavioral, and emotional problems). EBI strategies include: i) proactive behavioral management strategies; ii) social emotional promotion & regulation strategies; iii) managing misbehaviors & noncooperation; iv) school-family connection • **Other EBI strategies included in PD** : i) parent engagement strategies to strengthen school-home connection & support for students; ii) individual planning for supporting high-need students; and iii) coaching support in applying the EBI strategies.	
Implementation model	Mental health professionals (MHPs) from an academic institution and Department of Education (DOE) jointly implemented PD and Family program	**Localized Partnership Implementation Models** • **Uganda (Urban)**: MHPs and psychiatric nurses implemented *PD* • **Nepal (Rura**l): MHPs, community health workers (CHWs), and District Education Office staff implemented *PD*
Targets in the studies	Ethnically diverse Black, Latino & Asian children (aged 4- 6) from low-income urban communities	Ethnically diverse children (aged 3-10) from low-income families in urban Uganda and rural Nepal with diverse tribes and migration backgrounds
Impact evidence (*d*=effect size)	**Efficacy evidence for *ParentCorps*** (2 RCTs) • Teachers: EBI practices (*d* =.42-.85) • Children: Mental health at post and 3 years post intervention (*d*=.44-.56) • Parents: EBI practices *(d*=.16-.50)	**Efficacy evidence for PD** (immediate post intervention) • **Uganda** (RCT): Teachers: EBI practice (*d*=.55-1.03); Children: Mental health (*d*=.39-1.08); and Parents: EBI practices (*d*=.22-.56 through knowledge sharing). • **Nepal** (pre-post): Teachers: EBI practices (*d*=.32-.69); Children: Mental health (*d*=.20-.47), school functioning (*d*=.26-.43); Parents: EBI practices (*d*=.43-.79)

Note. See references in the paper [11, 15, 22, 26, 27, 96, 97]

Table S2. Power Estimation for Child and Teacher Effectiveness Outcomes

	Power Estimate Based on Two Regions							**Power Estimate Based on One Region**						
	Power Estimation for *Child* Effectiveness Outcomes							**Power Estimation for *Child* Effectiveness Outcomes**						
Cluster effect ICC	Estimate for **T2 to T3** Outcomes (assuming 20% loss to follow up by T3)					Estimate for **T2** Outcomes (assuming 100% followed)		Estimate for **T2 to T3** Outcomes (assuming 20% loss to follow up by T3)					Estimate for **T2** Outcomes (assuming 100% followed)	
	Effective sample (N*)	Detectable Effect Size Cohen's d when correlations ρs range from:				Effective sample (N*)	Detectable Effect Size Cohen's d	Effective sample (N*)	Detectable Effect Size Cohen's d when correlations ρs range from:				Effective sample (N*)	Detectable Effect Size Cohen's d
		ρ=.5	ρ=.6	ρ=.7	ρ=.8				ρ=.5	ρ=.6	ρ=.7	ρ=.8		
0	1056	.12	.11	.09	.08	1320	.15	528	0.17	0.15	0.13	0.11	660	0.22
0.01	738	.15	.13	.11	.09	857	.19	369	0.21	0.18	0.16	0.13	429	0.27
0.05	335	.22	.19	.17	.14	357	.21	168	0.31	0.27	0.24	0.19	178	0.42
	Power Estimation for *Teacher* Intermediate Outcomes							**Power Estimation for *Teacher* Intermediate Outcomes**						
Cluster effect ICC	Estimate for **T2 to T3** Outcomes (assuming 20% loss to follow up by T3)					Estimate for **T2** Outcomes (assuming 100% followed)		Estimate for **T2 to T3** Outcomes (assuming 20% loss to follow up by T3)					Estimate for **T2** Outcomes (assuming 100% followed)	
	Effective sample (N*)	Detectable Effect Size Cohen's d when correlations ρs range from:				Effective sample (N*)	Detectable Effect Size Cohen's d	Effective sample (N*)	Detectable Effect Size Cohen's d when correlations ρs range from:				Effective sample (N*)	Detectable Effect Size Cohen's d
		ρ=.5	ρ=.6	ρ=.7	ρ=.8				ρ=.5	ρ=.6	ρ=.7	ρ=.8		
0	312	.22	.20	.17	.14	360	.30	156	.32	.28	.25	.20	180	0.42
0.01	279	.24	.21	.18	.15	316	.32	139	.34	.30	.26	.21	158	0.45
0.05	195	.28	.25	.22	.18	212	.38	98	.40	.36	.31	.25	106	0.55

RESEARCH
Department of Health and Human Services
National Institutes of Health

NATIONAL INSTITUTE OF MENTAL HEALTH

Federal Award Date: 05/08/2020

Grant Number: 1R01MH122654-01
FAIN: R01MH122654

Principal Investigator(s):
Keng-Yen Huang (contact), PHD
Janet Nakigudde, PHD

Project Title: Effectiveness and Implementation of an Early Childhood School-Based Mental Health Intervention in Low-Resource Communities

McNamara, Morgan
Grants Manager
1 Park Avenue
6th Floor
New York, NY 100160000

Award e-mailed to: grants.office@med.nyu.edu

Period Of Performance:
Budget Period: 05/08/2020 – 02/28/2021
Project Period: 05/08/2020 – 02/29/2024

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of $674,506 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to NYU Grossman School of Medicine in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number R01MH122654. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Tamara A. Kees
Grants Management Officer
NATIONAL INSTITUTE OF MENTAL HEALTH

Additional information follows

SECTION I – AWARD DATA – 1R01MH122654-01

Award Calculation (U.S. Dollars)

Salaries and Wages	$131,793
Fringe Benefits	$42,937
Personnel Costs (Subtotal)	$174,730
Consultant Services	$42,600
Materials & Supplies	$8,600
Travel	$29,400
Other	$6,600
Subawards/Consortium/Contractual Costs	$213,160
Federal Direct Costs	$475,090
Federal F&A Costs	$199,416
Approved Budget	$674,506
Total Amount of Federal Funds Obligated (Federal Share)	$674,506
TOTAL FEDERAL AWARD AMOUNT	$674,506
AMOUNT OF THIS ACTION (FEDERAL SHARE)	$674,506

SUMMARY TOTALS FOR ALL YEARS		
YR	**THIS AWARD**	**CUMULATIVE TOTALS**
1	$674,506	$674,506
2	$647,952	$647,952
3	$642,371	$642,371
4	$563,496	$563,496

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name:	Mental Health Research Grants
CFDA Number:	93.242
EIN:	1135562309A1
Document Number:	RMH122654A
PMS Account Type:	P (Subaccount)
Fiscal Year:	2020

IC	CAN	2020	2021	2022	2023
MH	8472591	$674,506	$647,952	$642,371	$563,496

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:
PCC: 9G-GMH3 / **OC**: 41021 / **Released**: KEEST 05/01/2020
Award Processed: 05/08/2020 12:24:57 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01MH122654-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 1R01MH122654-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

c. 45 CFR Part 75.
d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2**.** As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01MH122654. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration System Information Website. NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made

publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.
Treatment of Program Income:
Additional Costs

SECTION IV – MH Special Terms and Conditions – 1R01MH122654-01

Clinical Trial Indicator: Yes
This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

RESTRICTION:
This award has been issued without a currently valid certification of IRB approval for one or more protocol(s). Only activities that are clearly severable and independent from activities that involve human subjects or activities for which IRB approval has been obtained may be conducted. Activities for the protocol(s) cited above may not be conducted until IRB approval of the protocol(s).

No funds may be drawn down from the payment management system and no obligations may be made against Federal funds for research involving human subjects for this protocol(s) prior to the IRB review and approval of this protocol(s). **Failure to comply with the terms and conditions of award may result in the disallowance of costs and collected data and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.**

INFORMATION:
This grant is awarded with the understanding that project delays and challenges may occur due to COVID-19. It is NIMH's intention to ensure the ultimate success of each project: to that end, we will work with recipients on a case-by-case basis to identify flexibilities and find solutions. You are encouraged to refer to the NIH Guide (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-086.html, and updates referenced therein) and to the regularly updated Frequently Asked Questions (https://grants.nih.gov/faqs#/covid-19.htm) for guidance on delays in research progress, delays in financial and RPPR reporting, costs, and other relevant issues, and contact your grants specialist and/or program officer with questions.

The NIH is concerned about the safety and welfare of human subject participants and research staff and has issued Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19 . For the purposes of RMR reporting, the NIMH requests that study teams continue to enter their anticipated recruitment milestones and actual recruitment numbers and succinctly indicate in the comments box if and how COVID-19 has impacted study recruitment efforts. NIMH staff will continue to monitor and work with you as additional guidance and information becomes available.

AWARD NOTICE:
This award has been made in response to the application submitted under the Funding Opportunity Announcement **MH18-701** which can be referenced at:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-701.html

INITIAL BUDGET PERIOD:
Although the budget period end date for this award is 02/28/2021, this award includes funds for 12-months of support. Subsequent budget periods will begin on **3/1** and will be 12-months in duration. Allowable pre-award costs may be charged to this award in accordance with the conditions outlined in the NIH Grants Policy Statement (http://grants.nih.gov/grants/policy/nihgps/index.htm) and in accordance with the recipient organization's requirements for prior approval.

HUMAN SUBJECTS RESEARCH

This award includes human subject research studies and must conform to the DHHS policies for the Protection of Human Subjects research, which are a term and condition of award. Human subjects research is covered by the 2018 Common Rule, and may not be initiated until the associated protocols have received IRB approval as specified in 45 CFR 46. Failure to comply with the terms and conditions of award may result in the disallowance of costs and collected data and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.

DATA SHARING PLAN:
This award is subject to the data sharing guidance outlined in NOT-MH-15-012 and can be found at
https://grants.nih.gov/grants/guide/notice-files/not-mh-15-012.html

Please note that NOT-MH-19-041 clarifies the timeline related to NIMH data sharing and can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-041.html. The recipient agrees to adhere to the resource and data sharing plan negotiated with NIMH Program staff. Dissemination of study data will be in accord with the Recipient's accepted data sharing plan as stated in page 255 of the application. **Please note that a statement of progress on the Sharing Plan must be included in the Research Performance Progress Report (RPPR) under section C.5 "Other Products and Resource Sharing."** Failure to adhere to the sharing plan as mutually agreed upon by the Recipient and the NIH/IC may result in Enforcement Actions as described in the NIH Grants Policy Statement.

Complete NIMH data sharing terms and conditions can be found at https://nda.nih.gov/contribute/sharing-regimen.html. Instructions are available at http://grants.nih.gov/grants/rppr/index.htm. Complete guidelines on data sharing are available at http://grants.nih.gov/grants/policy/data_sharing/index.htm.

DATA AND SAFETY MONITORING:
This grant is expected to involve a Data and Safety Monitoring Board (DSMB). The recipient and Principal Investigator(s) should review the NIMH Policy Governing Independent Safety Monitors and Independent Data and Safety Monitoring Boards cited in NOT-MH-19-027. Each RPPR submitted should include copies of all DSMB reports in RPPR Section G.1 since the last annual award. The recipient is also reminded of required reporting pursuant to NIHGPS 4.1.15.3 and the NIMH Reportable Events Policy cited in NOT-MH-19-027, as appropriate

PARTICIPANT RECRUITMENT - MILESTONES:
Future NIMH support for this study is contingent upon adequate participant recruitment based on projected milestones as approved in the Recruitment Milestone Reporting system (RMR) on 3/23/2020. It is expected that **60** of the **2,604** total projected participants will be recruited by **12/1/2020.** This tri-yearly recruitment report should be submitted electronically to NIMH after each milestone period of April 1, August 1 and December 1
at: http://wwwapps.nimh.nih.gov/rmr/displayHome.action. ; In the event that actual recruitment falls significantly below projected milestones, NIMH may consider withholding future support and/or negotiating an orderly phase-out of this study. Information regarding the NIMH Policy for the Recruitment of Participants in Clinical Research is available at:
https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-027.html.

CONSORTIUM / CONTRACTUAL COSTS:
This award includes funds for consortium activity with:

Global Health Uganda

Each consortium is to be established and administered in accordance with the NIH Grants Policy Statement (http://grants.nih.gov/grants/policy/nihgps/index.htm). No foreign performance site may be added to this project without the written prior approval of the National Institute of Mental Health.

GCP TRAINING:

NIH expects that all NIH-funded investigators and staff who are involved in the conduct, oversight, or management of clinical trials should be trained in Good Clinical Practice (GCP), consistent with principles of the International Conference on Harmonisation (ICH) as stated in NOT-OD-16-148.

CLINICAL TRIAL DISSEMINATION PLAN:
The clinical trial(s) supported by this award is subject to the plan within the competing application dated 6/13/2019 submitted to NIH and the NIH policy on Dissemination of NIH-Funded Clinical Trial Information. The plan states that the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and primary summary results reported in ClinicalTrials.gov, not later than one year after the completion date. The reporting of summary results is required by this term of award even if the primary completion date occurs after the period of performance.

CLINICAL TRIAL REQUIREMENTS:
This award is subject to additional certification requirements with each submission of the Annual, Interim, and Final Research Performance Progress Report (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the AOR signifies compliance, as follows:

In submitting this RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are in compliance with the recipient's plan addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the completion date, even if the completion date occurs after the period of performance.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Julie M. Bergerud
Email: julie.bergerud@nih.gov **Phone**: 301-827-6184

Program Official: Andrea De Fatima Horvath Marques
Email: andrea.horvathmarques@nih.gov **Phone**: 301-443-3945

SPREADSHEET SUMMARY
GRANT NUMBER: 1R01MH122654-01

INSTITUTION: NYU Grossman School of Medicine

Budget	Year 1	Year 2	Year 3	Year 4
Salaries and Wages	$131,793	$132,993	$143,355	$143,689
Fringe Benefits	$42,937	$43,329	$46,718	$46,668

Personnel Costs (Subtotal)	$174,730	$176,322	$190,073	$190,357
Consultant Services	$42,600	$17,600	$7,820	$2,820
Materials & Supplies	$8,600	$3,500	$3,500	
Travel	$29,400	$16,200	$16,200	$16,200
Other	$6,600	$6,600	$6,600	
Subawards/Consortium/Contractual Costs	$213,160	$270,438	$258,126	$204,364
Publication Costs		$2,500	$2,500	$2,500
TOTAL FEDERAL DC	$475,090	$493,160	$484,819	$416,241
TOTAL FEDERAL F&A	$199,416	$154,792	$157,552	$147,255
TOTAL COST	$674,506	$647,952	$642,371	$563,496

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4
F&A Cost Rate 1	69.5%	69.5%	69.5%	69.5%
F&A Cost Base 1	$286,930	$222,722	$226,693	$211,877
F&A Costs 1	$199,416	$154,792	$157,552	$147,255

NIH NGA R | Version: 56 - 12/26/2018 2:22:00 PM| Generated on: 5/8/2020 12:24:57 AM

NYU School of Medicine

Office of Science and Research
Institutional Review Board
1 Park Avenue | 6th Floor | New York, NY 10016

Approval of Submission

May 3, 2020

On 5/1/2020 the IRB reviewed and approved the following submission:

principal investigator	Keng-Yen Huang
study number	i20-00117
study title	Effectiveness and Implementation of an Early Childhood School-Based Mental Health Intervention in Low-Resource Communities
performance period	5/1/2020 - 4/30/2021
location(s)	Translational Research Building (NYUMC Locations), International (Other Locations)
sponsor(s)	Name: NIH-NIMH
review type	Initial Study [Expedited 6, 7]
board name	Reported to All Boards

3-MAY-2020

materials approved for use	• s20-00117SchoolStaff_Teachers_PTA_Consent3.2020.pdf, Category: Consent Form; • s20-00117Parent_Caregiver_Consent3.2020.pdf, Category: Consent Form; • s20-00117Teacher T-Wellness_MOST_Y1_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117 Child Assessment.docx, Category: IRB Protocol; • s20-00117 School Leadership Principals Assessment.docx, Category: IRB Protocol; • s20-00117SchoolLeadership_Principals_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117 Parent Assessment.docx, Category: IRB Protocol; • s20-00117SchoolStaff_Teachers_PTA_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117SchoolLeadership_Principals_Consent3.2020.pdf, Category: Consent Form; • 20-00117-R01_PD_IRB_protocol_4-21-2020.docx, Category: IRB Protocol; • s20-00117 Teacher T-Wellness_MOST_Y1_Assessment.docx, Category: IRB Protocol; • s20-00117Child_Assent7-11_Consent3.2020.pdf, Category: Consent Form; • s20-00117-international-research_March4_2020.docx, Category: Other; • s20-00117 School Staff- Teacher+PTA.docx, Category: IRB Protocol; • s20-00117 Intervention_Implementer_Trainer Assessment.docx, Category: IRB Protocol; • s20-00117Intervention_Implementers_Trainers_Consent3.2020.pdf, Category: Consent Form; • s20-00117Parent_Caregiver_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117Teacher T-Wellness_MOST_Y1_Consent3.2020.pdf, Category: Consent Form;

The current IRB Status of your submission is: Approved. This submission was reviewed by the NYU School of Medicine's Institutional Review Board (IRB). During the review of your study, the IRB specifically considered:

1. the risks and anticipated benefits (if any) to your subjects
2. the selection of subjects
3. the procedures for securing and documenting informed consent
4. the safety of your subjects
5. the privacy of your subjects and confidentiality of the data

Your study cannot commence until all ancillary review decisions are complete. To determine the state of all ancillary reviews, go the MyStudies page of this study in Research Navigator. Ancillary review statuses are located on the top/right area of your study's main screen.

Note: Ensure that approval has been issued in MyAgreements/CRMS and the Clinical Research Support Unit ("CRSU") before you proceed with any aspect of this study, including the enrollment of human subjects.

For questions regarding this submission, please contact Jasmine Liu at 646-754-4639 or Jasmine.Liu@nyulangone.org.

Thank you for using NYU SOM Institutional Review Board.

Review Notes

For NIH grant funded research approved before the revised Common Rule: the IRB has found the IRB approved protocol referenced above to be consistent with the NIH grant application.

Federalwide Assurance: FWA00004952

NYU School of Medicine's IRB operates in accordance with Good Clinical Practices (GCP) and applicable laws and regulations. Federal rules allow IRBs to document their determination/authorization process in their policy manual. Determination letters generated by NYU SoM's IRB administration system are not physically signed as per policy. All approved study materials are clearly identified and locked in each study submission record within the IRB's administration system.

NYU School of Medicine IRB Policy

- *All current IRB policy documents can be found on our website*
- *You must submit all modifications to this study (e.g., protocol updates, modified recruitment materials, consent forms, etc.) using Research Navigator to communicate with the IRB ("eSubmission") for review and approval prior to initiation of those change(s), except where necessary to eliminate apparent immediate hazards to the subject(s). Changes made to eliminate apparent immediate hazards to subjects must be reported to the IRB within 24 hours.*
- *All adverse and/or unanticipated event(s) that occur while conducting this study must immediately be reported to the IRB via eSubmission.*
- *You may only use IRB-approved copies of your consent form(s), questionnaire(s), letter(s), advertisement(s), etc. in your study. Never use expired consent forms.*
- *If modifications are made to the study or adverse events occur while conducting study, the PI must inform all research staff listed on this study.*
- *IRB's approval is valid as per the period indicated above. A reminder to submit a continuation (should one be required) will be e-mailed to the PI, PI Proxy and Primary Contact 90, 60 and 30 days prior to this study's expiration date if one is indicated. After expiration, a daily reminder will be sent for 30 days followed by a weekly reminder until the study receives re-approval or a study closure.*
- *Prior to initiating an IRB-approved study, you must receive written approval from an authorized representative for each site where your study will take place. Key contacts are:*
    - Bellevue Hospital (BHC): if you are conducting all or part of your study at BHC, you must contact them to obtain additional approvals. BHC will be notified if any of their sites are selected as a location where your study takes place, but your team is obligated to contact them at BellevueResearch@bellevue.nychhc.org to find out what approvals are required before conducting any research at a BHC location.
    - *CTSI - Clinical and Translational Science Institute, NYU School of Medicine [formerly General Clinical Research Center (GCRC)]: email ctsi@nyulangone.org*
    - *NYU Langone Health Centers (Tisch Hospital/Rusk Institute/Co-op Care/HJD/Perlmutter Cancer Center) site approval is handled for you automatically (as needed) by the CRSU*
- *The IRB may suspend or terminate studies that are not in compliance with NYU Langone Health/School of Medicine Policies & Procedures and the requirements of the Institution's Federal Wide Assurance with the federal government.*
- *Direct IRB questions and comments to 212-263-4110 or IRB-INFO@nyulangone.org*

IRB Board Rosters

Effective **2020-01-01** FWA#00004952
Quorum is simple majority only = greater than half

Board A (Effective 2020-01-01)

Members; Quorum of 8; 8 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
More, Frederick (Chair)	DDS	S	Dentistry – Pediatrics	Y	Hazen, Katz, Nishawala, Novik, Wissner-Greene
Donnino, Robert (Vice Chair)	MD	S	Medicine – Cardiology	Y	Vice Chair Alternates: Hazen, Nishawala, GreeneMember Alternates: Culliford, Katz
Basu Roy, Upal	PhD, MPH	S	Community Representative	N	Aswald, Raskin, Wu
Bliss, Samuel	PharmD	S	Pharmacy	Y	Ballani, Dubrobskaya, Faiena, Wong
Davies, Faith	MD	S	Oncology	Y	Du, Kwa, Moskovitz, Novik, Rapp, Ryan, Saint Fleur, Schiff, Wu
Diefenbach, Catherine	MD	S	Oncology	Y	Du, Kwa, Moskovitz, Novik, Rapp, Ryan, Saint Fleur, Schiff, Wu
Gallagher, Richard	PhD	S	Child & Adolescent Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Nishawala, Rotrosen
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Kadidal, Shane *	JD	NS	Law – Prisoner Advocate	N	Brown
Lamont, Justin	MD	S	Orthopedic Surgery	Y	Kirsch, Leucht, Rapp
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, McGowan, Vieira, Wallach
Ross-Rizzo, John	MD	S	Neurology	Y	Barr, Berk, Chervinsky, Duic, Lewis
Ross, Stephen	MD	S	Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Nishawala, Rotrosen
Storey, Elizabeth	PhD	S	Radiology	Y	Bartlett, Bencardino, Fieremans, Gonen
Wang, Jing	MD	S	Anesthesiology	Y	Kim

Counts toward quorum only when reviewing studies subject to Subpart C

3-MAY-2020

Board B (Effective 2020-01-01)

Members; Quorum of 9, 9 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
Katz, Stuart (Chairman)	MD PhD	S	Cardiology	Y	Donnino, Hazen, More, Nishawala, Novik, Wissner-Greene
Hazen, Alexes (Vice Chair)	MD	S	Surgery – Plastic	Y	Vice Chair Alternates: Donnino, More, Nishawala, Novik, Wissner-Greene Member Alternates: DeLacure
Bartlett, Rachel	PhD	S	Radiology	Y	Bencardino, Fieremans, Gonen, Storey
Berk, Thomas	MD	S	Neurology	Y	Barr, Duic, Lewis, Ross-Rizzo
Brar, Preneet	MD	S	Pediatric Endocrinology	Y	Ramirez, Tunik, Wissner-Greene
Culliford, Alfred	MD	S	Surgery – Cardiothoracic	Y	Donnino, Lamont, Rapp
Du, Kevin	PhD	S	Radiation Oncology	Y	Davies, Diefenbach, Kwa, Moskovitz, Novik, Rapp, Ryan, Saint Fleur, Schiff, Wu
Dubrovskaya, Yanina	PharmD	S	Pharmacy	Y	Ballani, Bliss, Faiena, Wong
Frankle, William Gordon	MD	S	Psychiatry	Y	Barr, Bogenschutz, Gallagher, Nishawala, Ross, Rotrosen
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez Johnson
Kadidal, Shane *	JD	NS	Law-Prisoner Advocate	N	Brown
Kirsch, Thorsten	PhD	S	Orthopedic Surgery	Y	Lamont, Leucht, Rapp
Kwa, Maryann	MD	S	Oncology	Y	Davies, Diefenbach, Moskovits, Novik, Rapp, Ryan, Saint Fleur, Schiff, Wu
McGowan, Richard	MLS	NS	Public Services	Y	Vieira
Nolan, Anna	MD	S	Pulmonary	Y	
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, Vieira, Wallach
Raskin, Joyce	JD	NS	Community Representative	Y	Aswald, Basu Roy, Wu

**Counts toward quorum only when reviewing studies subject to Subpart C*

3-MAY-2020

Board C (Effective 2020-01-01)

Members; Quorum of 7; 7 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
Novik, Yelena (Chair)	MD	S	Oncology	Y	Donnino, Hazen, Katz, More, Nishawala, Wissner-Greene
Nishawala, Melissa (Vice Chair)	MD	S	Child & Adolescent Psychiatry	Y	Vice Chair Alternates: Donnino, Hazen, Katz, More, Wissner-Greene Member Alternates: Barr, Bogenschutz, Chervinsky, Frankle, Gallagher, Ross, Rotrosen
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Goddard, David H	MD	S	Rheumatology	Y	
Chervinsky, Alexander B	PhD	S	Neuropsychology	Y	Barr, Bogenschutz, Gallagher, Lewis, Nishawala, Ross, Rotrosen
Kadidal, Shane *	JD	NS	Law – Prisoner Advocate	N	Brown
Kim, Sunmi	MD	S	Anesthesiology	Y	Wang
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, McGowan, Wallach
Schiff, Peter	MD	S	Radiation Oncology	Y	Davies, Diefenbach, Du, Kwa, Moskovits, Rya, Saint Fleur
Vieira, Dorice	MA	NS	Public Services	Y	McGowan
Wong, Doris	PharmD	S	Pharmacy	Y	Ballani, Bliss, Dubrovskaya, Faiena
Wu, Jennifer	MD	S	Oncology	Y	Davies, Diefenbach, Du, Kwa, Moskovits, Ryan, Saint Fleur
Wu, Lillian	BA, MA	NS	Community Representative	N	Aswald, Basu Roy, Raskin

**Counts toward quorum only when reviewing studies subject to Subpart C*

3-MAY-2020

Board D (Effective 2020-01-01)

Members; Quorum of 8; 9 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
More, Frederick (Chair)	DDS	S	Dentistry – Pediatrics	Y	Donnino, Hazen, Katz, Nishawala, Novik, Wissner-Greene
Wissner-Greene, Loren (Vice Chair)	MD, MA	S	Medicine – Endocrinology – Ob-Gyn	Y	Vice Chair Alternates: Donnino, Hazen, Katz, More, Nishawala, Novik, Member Alternate: Brar
Aswald, Brahim	BS	NS	Community Representative	N	Basu Roy, Raskin, Wu
Ballani, Kanika	PharmD	S	Pharmacy	Y	Bliss, Dubrovskaya, Faiena, Wong
Barr, William	PhD	S	Neuropsychology	Y	Berk, Chervinsky, Frankle, Gallagher, Lewis, Nishawala, Ross, Ross-Rizzo, Rotrosen,
Bogenschutz, Michael	MD	S	Psychiatry	Y	Chervinsky, Frankle, Gallagher, Nishawala, Ross, Rotrosen
Dedania, Vaidehi	MD	S	Ophthalmology	Y	
Duic, Julius	MD	S	Neuro-Oncology	Y	Berk, Davies, Diefenbach, Du Kwa, Novik, Rapp,Ross-Rizzo, Ryan, Schiff, Wu
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Gonen, Oded	PhD	S	Radiology	Y	Bartlett, Bencardino, Fieremans, Storey
Kadidal, Shane *	JD	NS	Legal – Prisoner Advocate	N	Brown
Leucht, Philipp	MD, PhD	S	Orthopaedic Trauma	Y	Kirsch, Lamont, Rapp
Mehta-Lee, Shilpi	MD	S	Ob-Gyn	Y	
Panageas, Helen		NS	IRB Administration	Y	Dvorkin, Liu, McGowan, Vieira, Wallach
Ramirez, Michelle	MD	S	Pediatric Critical Care	Y	Brar, Oshva, Tunik
Saint Fleur, Shella	MD	S	Oncology	Y	Davies, Diefenbach, Du Kwa, Novik, Rapp, Ryan, Schiff, Wu

**Counts toward quorum only when reviewing studies subject to Subpart C*

3-MAY-2020

Board E (Effective 2020-01-01)

Members; Quorum of 4; 4 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
More, Frederick (Chair)	DDS	S	Dentistry	Y	Donnino, Hazen, Katz, Nishawala, Novik, Wissner-Greene
Katz, Stuart (Vice-Chair)	MD	S	Cardiology	Y	Vice Chair Alternates: Donnino, Hazen, More, Nishawala, Novik, Wissner-Greene Member Alternates: Culliford, Donnino
Johnson, Nadia	MS	S	IRB Administration	Y	Berkovitz, Godina, Jeschke-Lopez
Wu, Jennifer	MD	S	Oncology	Y	Davies, Diefenbach, Du, Duic, Kwa, Moskovits, Novik, Rapp, Ryan, Saint Fleur, Schiff
Kadidal, Shane *	JD	NS	Law-Prisoner Advocate	N	Brown
Panageas, Helen		NS	IRB Administration	Y	Dvorkin, Liu, McGowan, Vieira, Wallach
Raskin, Joyce	JD	NS	Community Representative	Y	Aswald, Basu Roy, Wu

**Counts toward quorum only when reviewing studies subject to Subpart C*

3-MAY-2020

Alternates

Alternate	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate For
Aswald, Brahim	MS	NS	Community Representative	N	Basu Roy, Raskin, Wu
Ballani, Kanika	PharmD	S	Pharmacy	Y	Bliss, Dubrovskaya, Wong
Barr, William	PhD	S	Neuropsychology	Y	Berk, Chevinsky, Frankle, Gallagher, Nishawala, Ross, Ross-Rizzo
Bartlett, Rachel	PhD	S	Radiology	Y	Gonen, Storey
Basu Roy, Upal	PhD, MPH	S	Community Representative	Y	Aswald, Raskin, Wu
Bencardino, Jenny	MD	S	Radiology	Y	Bartlett, Gonen, Schiff
Berk, Thomas	MD	S	Neurology	Y	Barr, Duic, Ross-Rizzo
Berkovitz, David	MD	S	IRB Administration	Y	Godina
Bliss, Samuel	PharmD	S	Pharmacy	Y	Ballani, Dubrovskaya, Wong
Bogenschutz, Michael	MD	S	Psychiatry	Y	Barr, Chervinsky, Frankle, Gallagher, Nishawala, Ross
Brar, Preneet	MD	S	Pediatric Endocrinology	Y	Ramirez, Wissner-Greene
Brown, Justin	MHA	NS	Prisoner Advocate	Y	Kadidal
Chervinsky, Alexander	PhD	S	Neuropsychology	Y	Barr, Bogenschutz, Gallagher, Nishawala, Ross, Ross-Rizzo
Culliford, Alfred	MD	S	Surgery – Cardiothoracic	Y	Donnino, Katz
Davies, Faith	MD	S	Oncology	Y	Du, Duic, Kwa, Saint Fleur, Schiff, Wu
DeLacure, Mark D	MD	S	Otolaryngology & Plastic Surgery	Y	Hazen
Diefenbach, Catherine	MD	S	Oncology	Y	Du, Duic, Kwa, Saint Fleur, Schiff, Wu
Donnino, Robert	MD	S	Medicine – Cardiology	Y	Culliford Hazen, Katz, More, Nishawala, Novik, Wissner-Greene
Du, Kevin	PhD	S	Radiation Oncology	Y	Davies, Diefenbach, Duic, Kwa, Saint Fleur, Schiff, Wu
Dubrovskaya, Yanina	PharmD	S	Pharmacy	Y	Ballani, Bliss, Wong
Duic, Julius P	MD	S	Neuro-Oncology	Y	Berk, Davies, Diefenbach, Du Kwa, Novik, Rapp,Ross-Rizzo, Ryan, Schiff, Wu
Dvorkin, Ella		NS	IRB Administration	Y	Panageas
Faiena, Mark	PharmD	S	Pharmacy	Y	Ballani, Bliss, Dubrovskaya, Wong
Fieremans, Els	PhD		Radiology	Y	Bartlett, Gonen, Storey
Frankle, William Gordon	MD	S	Psychiatry	Y	Barr, Bogenschutz, Gallagher, Nishawala, Ross
Gallagher, Richard	PhD	S	Child & Adolescent Psychiatry	Y	Chervinsky, Frankle, Nishawala, Ross
Gonen, Oded	PhD	S	Radiology	Y	Bartlett, Storey
Hazen, Alexes	MD	S	Plastic Surgery	Y	Katz, More, Nishawala, Novik, Wissner-Greene
Jeschke-Lopez, Ikoa	MD	S	IRB Administration	Y	Godina
Johnson, Nadia	MS	S	IRB Administration	Y	Godina
Katz, Stuart	MD	S	Cardiology	Y	Donnino, Hazen, More, Nishawala, Novik, Wissner-Greene
Kim, Sunmi	MD	S	Anesthesiology	Y	Wang
Kirsch, Thorsten	MD	S	Orthopedic Surgery	Y	Lamont, Leucht, Rapp

3-MAY-2020

Kwa, Maryann	MD	S	Oncology	Y	Davies, Diefenbach, Du, Duic,Novik, Saint Fleur, Schiff, Wu
Lamont, Justin	MD	S	Orthopedic Surgery	Y	Culliford, Hazen, Kirsch, Leucht, Rapp
Leucht, Philipp	MD, PhD	S	Orthopaedic Trauma	Y	Kirsch, Lamont, Schiff
Liu, Jasmine	BS	NS	IRB Administration	Y	Panageas
Lewis, Ariane	MD	S	Neurocritical Care	Y	Barr, Berk, Ross-Rizzo
McGowan, Richard	MLS	NS	Public Services	Y	Panageas, Vieira
More, Frederick	DDS	S	Dentistry – Pediatric	Y	Hazen, Katz, Nishawala, Novik, Wissner-Greene
Moskovits, Tibor	MD	S	Hematology – Oncology	Y	Diefenbach, Du, Duic, Kwa, Saint Fleur, Schiff, Wu
Nishawala, Melissa	MD	S	Child & Adolescent Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Hazen, Katz, More, Novik, Ross, Wissner-Greene
Nolan, Anna	MD	S	Pulmonary	Y	
Novik, Yelena	MD	S	Oncology	Y	Davies, Diefenbach, Du, Duic, Katz, Kwa, Hazen, More, Nishawala, Saint Fleur, Wissner-Greene, Wu
Oshva, Lillian	MD	S	Emergency Medicine	Y	Ramirez
Ramirez, Michelle	MD	S	Pediatric Critical Care	Y	Brar
Rapp, Timothy	MD	S	Orthopedic Surgery – Oncology	Y	Culliford, Davies, Diefenbach, Du, Duic, Kirsch, Kwa, Lamont, Leucht, Saint Fleur, Schiff, Wu
Raskin, Joyce	JD	NS	Community Representative	Y	Aswald, Basu Roy, Wu
Ross, Stephen	MD	S	Addiction Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Nishawala
Ross-Rizzo, John	MD	S	Neurology	Y	Barr, Chervinsky, Duic
Rotrosen, John	MD	S	Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Gallagher, Nishawala, Ross
Ryan, Theresa	MD	S	Oncology	Y	Davies, Diefenbach, Du, Duic, Kwa, Novik, Saint Fleur, Schiff, Wu
Saint Fleur, Shella	MD	S	Hematology - Oncology	Y	Davies, Diefenbach, Du, Duic, Kwa, Novik, Schiff, Wu
Schiff, Peter	MD	S	Radiation – Oncology	Y	Davies, Diefenbach, Du, Duic, Kwa, Saint Fleur, Wu
Storey, Elizabeth	PhD	S	Radiation	Y	Bartlett, Gonen
Tunik, Michael	MD	S	Pediatric EM	Y	Brar, More, Ramirez
Vieira, Dorice	MA	NS	Public Services	Y	McGowan, Panageas
Wallach, David	BA , MPH	NS	IRB Administration	Y	Panageas
Wang, Jing	MD	S	Anesthesiology	Y	Kim
Wissner-Greene, Loren	MD, MA	S	Medicine – Endocrinology – Ob-Gyn	Y	Brar, Hazen, Katz, More, Nishawala, Novik,
Wong, Doris	PharmD	S	Pharmacy	Y	Ballani, Bliss, Dubrovskaya,
Wu, Jennifer	MD	S	Oncology	Y	Davies, Diefenbach, Du, Duic, Kwa, Saint Fleur
Wu, Lillian	BA, MA	NS	Community Representative	N	Aswald, Basu Roy, Raskin

3-MAY-2020

MAKERERE UNIVERSITY
P.O. Box 7072 Kampala, Uganda
E-mail: rresearch9@gmail.com
Phone: 256 414 533541
Fax: 256 414 541036/0414 532204

COLLEGE OF HEALTH SCIENCES
SCHOOL OF MEDICINE

RESEARCH ETHICS COMMITTEE

August 17, 2020

Dr. Janet Nakigudde
Department of Psychiatry

Category of Review
[X] Initial review
[X] Full board review
[ ] Expedited review
[ ] Continuing review
[ ] Amendment
[ ] Termination of study
[ ] SAEs

Dear Dr. Nakigudde,

Re: Approval of proposal #REC REF 2020-143

"Effectiveness and Implementation of an Early Childhood School-Based Mental Health Intervention in Low-Resource Communities in Hoima and Kampala districts-Uganda"

Thank you for submitting an application for approval of the above – referenced **proposal**. The committee reviewed it and granted approval for one-year, effective August 17th, 2020. Approval will expire on August 16th, 2021.

Continuing Review
In order to continue work on this study (including data analysis) beyond the expiration date, the School of Medicine Research and Ethics Committee must reapprove the protocol after conducting a substantive, meaningful, continuing review. This means that you must submit a continuing report form as a request for continuing review. To best avoid a lapse, you should submit the request six (6) weeks before the lapse date. Please use the forms supplied by our office.

Amendments
During the approval period, if you propose any change to the protocol such as its funding source, recruiting materials, or consent documents, you must seek School of Medicine Research and Ethics Committee approval before implementing it.

Please summarize the proposed change and the rationale for it in a letter to the School of Medicine Research and Ethics Committee. In addition, submit three (3) copies of an updated version of your original protocol application- one showing all proposed changes in bold or 'track changes,' and the other without bold or track changes.

Reporting

Other events which must be reported promptly in writing to the School of Medicine Research and Ethics Committee include:

Suspension or termination of the protocol by you or the grantor

Unexpected problems involving risk to participants or others

Adverse events, including unanticipated or anticipated but severe physical harm to participants.

Do not hesitate to contact us if you have any questions. Thank you for your cooperation and commitment to the protection of human subjects in research.

Documents approved for use along with the protocol

- English and translated informed consent form
- English and translated parental/guardian informed consent form
- English and translated assent form
- Data collection tools

Please Note:

1. Final approval is to be granted by Uganda National Council for Science and Technology.
2. All the study documents including the revised proposal, Informed Consent Forms, Data Collection Tools and any other study documents should be stamped by the REC.
3. Approval from National Drug Authority should be sought where applicable.
4. Approval for use of research devices should be sought from the Ministry of Health/Uganda National Council for Science and Technology where applicable.
5. Administrative clearance should be sought from the various study sites.
6. This study will be monitored by the School of Medicine Research Ethics Committee to assess for compliance to both national and international research guidelines for protecting the rights and welfare of research participants.
7. The REC should be involved in the dissemination of study findings to the different stakeholders. (This applies to staff research, collaborative research and PhD students).
8. The REC should be informed and involved in the process of study closure.

Yours sincerely,

MAKERERE UNIVERSITY
SCHOOL OF MEDICINE
APPROVED
VALID UNTIL
16 AUG 2021
RESEARCH & ETHICS COMMITTEE
P.O.BOX 7072, KAMPALA

Assoc. Prof. Ponsiano Ocama
Chairperson School of Medicine Research and Ethics Committee

Uganda National Council for Science and Technology
(Established by Act of Parliament of the Republic of Uganda)

Our Ref: HS1057ES **18 December 2020**

Janet Nakigudde
Makerere College of Health Sciences
Kampala

Re: Research Approval: **Effectiveness and Implementation of an Early Childhood School-Based Mental Health Intervention in Low-Resourced Communities in Hoima and Kampala districts-Uganda**

I am pleased to inform you that on **18/12/2020**, the Uganda National Council for Science and Technology (UNCST) approved the above referenced research project. The Approval of the research project is for the period of **18/12/2020** to **18/12/2024**.

Your research registration number with the UNCST is **HS1057ES**. Please, cite this number in all your future correspondences with UNCST in respect of the above research project. As the Principal Investigator of the research project, you are responsible for fulfilling the following requirements of approval:

1. Keeping all co-investigators informed of the status of the research.

2. Submitting all changes, amendments, and addenda to the research protocol or the consent form (where applicable) to the designated Research Ethics Committee (REC) or Lead Agency for re-review and approval **prior** to the activation of the changes. UNCST must be notified of the approved changes within five working days.

3. For clinical trials, all serious adverse events must be reported promptly to the designated local REC for review with copies to the National Drug Authority and a notification to the UNCST.

4. Unanticipated problems involving risks to research participants or other must be reported promptly to the UNCST. New information that becomes available which could change the risk/benefit ratio must be submitted promptly for UNCST notification after review by the REC.

5. Only approved study procedures are to be implemented. The UNCST may conduct impromptu audits of all study records.

6. An annual progress report and approval letter of continuation from the REC must be submitted electronically to UNCST. Failure to do so may result in termination of the research project.

Please note that this approval includes all study related tools submitted as part of the application as shown below:

No.	Document Title	Language	Version Number	Version Date
1	Advisory Board Consent	English	1	04 November 2020
2	teacher Informed consent	English	1	04 November 2020
3	Teacher wellness consent	English	1	04 November 2020
4	teacher wellness	English	1	04 November 2020
5	Child assent	Runyoro	2	16 December 2020
6	parent consent	English	2	16 December 2020
7	program facilitator consent	English	2	16 December 2020
8	Teacher informed consent	English	2	16 December 2020
9	Teacher wellness consent	English	2	16 December 2020
10	Project Proposal	English	1	
11	Approval Letter	English	1	2020-11-05
12	Administrative Clearance	English	1	2020-11-05
12	Advisory Board Consent	English	2	16 December 2020
13	Assent form	English	2	16 December 2020
14	child assent	Runyoro	2	16 December 2020
15	child assent	Luganda	2	16 December 2020
16	Consent form	English	Parent consent	16 December 2020
17	Parent consent	Luganda	2	16 December 2020
18	Parent consent	Runyoro	2	16 December 2020
19	Program Facilitator Consent	English	2	16 December 2020
20	PTC Participant agreement	English	2	16 December 2020
21	Teacher Informed Consent	English	2	16 December 2020
22	Teacher wellness consent form	English	2	16 December 2020

Yours Sincerely



Hellen Opolot
For: Executive Secretary
UGANDA NATIONAL COUNCIL FOR SCIENCE AND TECHNOLOGY

LOCATION/CORRESPONDENCE

Plot 6 Kimera Road, Ntinda
P.O. Box 6884
KAMPALA, UGANDA

COMMUNICATION

TEL: (256) 414 705500
FAX: (256) 414-234579
EMAIL: info@uncst.go.ug
WEBSITE: http://www.uncst.go.ug

NYU Langone Health

Office of Science and Research
Institutional Review Board
1 Park Avenue | 6th Floor | New York, NY 10016

Approval of Submission

March 25, 2021

On 3/25/2021 the IRB reviewed and approved the following submission:

principal investigator	Keng-Yen Huang
study number	i20-00117_CR1
study title	Effectiveness and Implementation of an Early Childhood School-Based Mental Health Intervention in Low-Resource Communities
performance period	3/25/2021 - 3/24/2022
location(s)	Translational Research Building (NYUMC Locations), International (Other Locations)
sponsor(s)	Name: NIH-NIMH
review type	Continuing Review [Expedited categories 6,7]
board name	Reported to all boards

25-MAR-2021

materials approved for use	• s20-00117Parent_Caregiver_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117SchoolStaff_Teachers_PTA_Consent3.2020.pdf, Category: Consent Form; • s20-00117 Intervention_Implementer_Trainer Assessment.docx, Category: IRB Protocol; • 20-00117-R01_PD_IRB_protocol Amened 8.7.2020.docx, Category: IRB Protocol; • s20-00117Parent_Caregiver_Consent3.2020.pdf, Category: Consent Form; • s20-00117 School Leadership Principals Assessment.docx, Category: IRB Protocol; • s20-00117 Parent Assessment.docx, Category: IRB Protocol; • s20-00117 Teacher T-Wellness_MOST_Y1_Assessment.docx, Category: IRB Protocol; • s20-00117 Child Assessment.docx, Category: IRB Protocol; • s20-00117Intervention_Implementers_Trainers_Consent3.2020.pdf, Category: Consent Form; • s20-00117SchoolStaff_Teachers_PTA_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117Teacher T-Wellness_MOST_Y1_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117-international-research_March4_2020.docx, Category: Other; • s20-00117SchoolLeadership_Principals_Consent3.2020.pdf, Category: Consent Form; • s20-00117 School Staff- Teacher+PTA.docx, Category: IRB Protocol; • s20-00117SchoolLeadership_Principals_InformationSheet3.2020.pdf, Category: Consent Form; • s20-00117Child_Assent7-11_Consent3.2020.pdf, Category: Consent Form; • s20-00117Teacher T-Wellness_MOST_Y1_Consent3.2020.pdf, Category: Consent Form;
Link to Study	Open study in web browser

The current IRB Status of your submission is: Approved.

This submission was reviewed by the NYU Langone Health Institutional Review Board (IRB) referenced above. During the review of your study, the IRB specifically considered:

1. the risks and anticipated benefits (if any) to your subjects
2. the selection of subjects
3. the procedures for securing and documenting informed consent
4. the safety of your subjects
5. the privacy of your subjects and confidentiality of the data

Your study cannot commence until all ancillary review decisions are complete. To determine the state of all ancillary reviews, go the MyStudies page of this study in Research Navigator. Ancillary review statuses are located on the top/right area of your study's main screen.

Note: Ensure that approval has been issued in MyAgreements/CRMS and the Clinical Research Support Unit ("CRSU") before you proceed with any aspect of this study, including the enrollment of human subjects.

NYU Langone Health maintains a financial disclosure process by which researchers must disclose any personal financial interest that may be related to the research. Disclosures must be completed and submitted even if no Financial Interests are disclosed. One or more researchers on this study have not submitted disclosures and/or the Conflict of Interest Management Unit (CIMU) has not finalized its decision. Should CIMU require a new or revised Management Plan, submit a modification with the final CIMU determination to the IRB for review and approval, including any revised documents, if applicable.

For questions regarding this submission, please contact ***Nadine Meyers-Jack at 646-754-7306 and nadine.meyers-jack@nyulangone.org.***
Thank you for using the IRB at NYU Langone Health.

Review Notes

For NIH grant funded research approved before the revised Common Rule: the IRB has found the IRB approved protocol referenced above to be consistent with the NIH grant application

NYU Grossman School of Medicine Federal wide Assurance: FWA00004952
NYU Winthrop/Long Island School of Medicine Federal wide Assurance: FWA00000726

NYU Langone Health operates in accordance with Good Clinical Practices (GCP) and applicable laws and regulations. Federal rules allow IRB to document their determination/authorization process in their policy manual. Determination letters generated by NYU Langone Health IRB administration system are not physically signed as per policy. All approved study materials are clearly identified and locked in each study submission record within the IRB's administration system.

NYU Langone Health IRB Policy

- *All current IRB policy documents can be found on our website*
- *You must submit all modifications to this study (e.g., protocol updates, modified recruitment materials, consent forms, etc.) using Research Navigator to communicate with the IRB ("eSubmission") for review and approval prior to initiation of those change(s), except where necessary to eliminate apparent immediate hazards to the subject(s). Changes made to eliminate apparent immediate hazards to subjects must be reported to the IRB within 24 hours.*
- *All adverse and/or unanticipated event(s) that occur while conducting this study must immediately be reported to the IRB via eSubmission.*
- *You may only use IRB-approved copies of your consent form(s), questionnaire(s), letter(s), advertisement(s), etc. in your study. Never use expired consent forms.*
- *If modifications are made to the study or adverse events occur while conducting study, the PI must inform all research staff listed on this study.*
- *IRB's approval is valid as per the period indicated above. A reminder to submit a continuation (should one be required) will be e-mailed to the PI, PI Proxy and Primary Contact 90, 60 and 30 days prior to this study's expiration*

date if one is indicated. After expiration, a daily reminder will be sent for 30 days followed by a weekly reminder until the study receives re-approval or a study closure.

- *Prior to initiating an IRB-approved study, you must receive written approval from an authorized representative for each site where your study will take place. Key contacts are:*
  - *Bellevue Hospital (BHC): if you are conducting all or part of your study at BHC, you must contact them to obtain additional approvals. BHC will be notified if any of their sites are selected as a location where your study takes place, but your team is obligated to contact them at BellevueResearch@bellevue.nychhc.org to find out what approvals are required before conducting any research at a BHC location.*
  - *CTSI - Clinical and Translational Science Institute, NYU School of Medicine [formerly General Clinical Research Center (GCRC)]: email ctsi@nyulangone.org*
  - *NYU Langone Health Centers (Tisch Hospital/Rusk Institute/Co-op Care/HJD/Perlmutter Cancer Center) site approval is handled for you automatically (as needed) by the CRSU*
- *The IRB may suspend or terminate studies that are not in compliance with NYU Langone Health IRBs Policies & Procedures and the requirements of the Institution's Federal Wide Assurance with the federal government.*
- *Direct IRB questions and comments to 212-263-4110 or IRB-INFO@nyulangone.org*

Let Us Know How We're Doing

Click on the title above to send us feedback via a short, anonymous survey. Providing exceptional customer service is a top priority of the IRB and your responses will help us understand how we can continue to improve our service to the research community.

IRB Board Rosters

Effective **2021-03-01** FWA#00004952
Quorum is simple majority only = greater than half

Board A (Effective 2021-03-01)

Members; Quorum of 8; 8 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
More, Frederick (Chair)	DDS	S	Dentistry – Pediatrics	Y	Goddard, Hazen, Katz, Nishawala, Novik, Trinh
Donnino, Robert (Vice Chair)	MD	S	Medicine – Cardiology	Y	Vice Chair Alternates: Hazen, Nishawala, Member Alternates: Katz, Kerwin
Basu Roy, Upal	PhD, MPH	S	Community Representative	N	Bee, Raskin, Wu(Lillian)
Bliss, Samuel	PharmD	S	Pharmacy	Y	Dubrobskaya, Vasile, Wong
Davies, Faith	MD	S	Oncology	Y	Du, Garrison, Kwa, Moskovits, Novik, O'Keeffe, Ryan, Saint Fleur, Schiff, Wu
Diefenbach, Catherine	MD	S	Oncology	Y	Du, Garrison, Kwa, Moskovits, Novik, O'Keeffe Ryan, Saint Fleur, Schiff, Wu
Gallagher, Richard	PhD	S	Child & Adolescent Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Nishawala, Rotrosen
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Kadidal, Shane *	JD	NS	Law – Prisoner Advocate	N	Brown
Lamont, Justin	MD	S	Orthopedic Surgery	Y	Aggarwal, Kirsch
Laury, Sarah	BA	NS	Community Representative	Y	Bee, Raskin, Wu(Lillian)

Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, Mann, McGowan, Maril, Pogorelec-Khan, Redmond, Vieira,
Ross, Stephen	MD	S	Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Nishawala, Rotrosen
Storey, Elizabeth	PhD	S	Radiology	Y	Bartlett, Fieremans, Gonen
Wang, Jing	MD	S	Anesthesiology	Y	Kim

Counts toward quorum only when reviewing studies subject to Subpart C

25-MAR-2021

Board B (Effective 2021-03-01)

Members; Quorum of 8, 9 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
Katz, Stuart (Chairman)	MD PhD	S	Cardiology	Y	Donnino, Goddard, Hazen, More, Nishawala, Novik, Trinh
Hazen, Alexes (Vice Chair)	MD	S	Surgery – Plastic	Y	Vice Chair Alternates: Donnino, More, Nishawala, Novik, Petrone
Bartlett, Rachel	PhD	S	Radiology	Y	Fieremans, Gonen, Storey
Berk, Thomas	MD	S	Neurology	Y	Barr, Lewis, Ross-Rizzo
Brar, Preneet	MD	S	Pediatric Endocrinology	Y	Ramirez, Saenger, Tunik,
Du, Kevin	MD, PhD	S	Radiation Oncology	Y	Davies, Diefenbach, Garrison, Kwa, Moskovitz, Novik, O'Keeffe, Ryan, Saint Fleur, Schiff, Wu
Dubrovskaya, Yanina	PharmD	S	Pharmacy	Y	Bliss, Vasile, Wong
Frankle, William Gordon	MD	S	Psychiatry	Y	Barr, Bogenschutz, Gallagher, Nishawala, Ross, Rotrosen
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Kadidal, Shane *	JD	NS	Law-Prisoner Advocate	N	Brown
Kirsch, Thorsten	PhD	S	Orthopedic Surgery	Y	Aggarwal, Lamont
Kwa, Maryann	MD	S	Oncology	Y	Davies, Diefenbach, Garrison, Moskovits, Novik, O'Keeffe Ryan, Saint Fleur, Schiff, Wu
McGowan, Richard	MLS	NS	Public Services	Y	Vieira
Nolan, Anna	MD	S	Pulmonary	Y	Cataletto
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, Mann, Maril, Pogorelec-Khan, Redmond, Vieira

Raskin, Joyce	JD	NS	Community Representative	N	Basu Roy, Bee, Laury, Wu(Lillian)

**Counts toward quorum only when reviewing studies subject to Subpart C*

25-MAR-2021

Board C (Effective 2021-03-01)

Members; Quorum of 6; 7 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
Novik, Yelena (Chair)	MD	S	Oncology	Y	Donnino, Goddard, Hazen, Katz, More, Nishawala, Trinh
Nishawala, Melissa (Vice Chair)	MD	S	Child & Adolescent Psychiatry	Y	Vice Chair Alternates: Donnino, Hazen, Katz, More Member Alternates: Barr, Bogenschutz, Chervinsky, Frankle, Gallagher, Ross, Rotrosen
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Chervinsky, Alexander B	PhD	S	Neuropsychology	Y	Barr, Bogenschutz, Gallagher, Lewis, Nishawala, Ross, Rotrosen
Kadidal, Shane *	JD	NS	Law – Prisoner Advocate	N	Brown
Kim, Sunmi	MD	S	Anesthesiology	Y	Wang
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, Mann, Maril, McGowan, Pogorelec-Khan, Redmond, Vieira
Schiff, Peter	MD	S	Radiation Oncology	Y	Davies, Diefenbach, Du, Garrison, Kwa, Moskovits, O'Keeffe, Ryan, Saint Fleur
Vieira, Dorice	MA	NS	Public Services	Y	McGowan
Wong, Doris	PharmD	S	Pharmacy	Y	Bliss, Dubrovskaya, Vasile
Wu, Jennifer	MD	S	Oncology	Y	Davies, Diefenbach, Du, Garrison, Kwa, Moskovits, O'Keeffe, Ryan, Saint Fleur

Wu, Lillian	BA, MA	NS	Community Representative	N	Basu Roy, Bee, Laury, Raskin

**Counts toward quorum only when reviewing studies subject to Subpart C*

25-MAR-2021

Board D (Effective 2021-03-01)

Members; Quorum of 7; 7 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
Trinh, Chau (Chair)	DrPH	S	Population Health	Y	Donnino,Goddard, Hazen, Katz, More, Nishawala, Novik
Aggarwal, Vinay	MD	S	Orthopedic Surgery	Y	Kirsch, Lamont, Petrone
Barr, William	PhD	S	Neuropsychology	Y	Berk, Chervinsky, Frankle, Gallagher, Lewis, Nishawala, Ross, Ross-Rizzo, Rotrosen,
Bogenschutz, Michael	MD	S	Psychiatry	Y	Chervinsky, Frankle, Gallagher, Nishawala, Ross, Rotrosen
Dedania, Vaidehi	MD	S	Ophthalmology	Y	
Godina, Marina	RN	S	IRB Administration; Nursing	Y	Berkovitz, Jeschke-Lopez, Johnson
Gonen, Oded	PhD	S	Radiology	Y	Bartlett, Fieremans, Storey
Kadidal, Shane *	JD	NS	Legal – Prisoner Advocate	N	Brown
Laury, Sarah	BA	NS	Community Representative	Y	Bee, Raskin, Wu(Lillian)
Mehta-Lee, Shilpi	MD	S	Ob-Gyn	Y	Kuokkanen, Wissner-Greene
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, Mann, Maril, McGowan, Pogorelec-Khan, Redmond, Vieira
Ramirez, Michelle	MD	S	Pediatric Critical Care	Y	Brar, Cataletto, Oshva, Tunik

Saint Fleur, Shella	MD	S	Oncology	Y	Davies, Diefenbach, Du, Garrison Kwa, Moskovits, Novik, O'Keeffe, Ryan, Schiff, Wu

**Counts toward quorum only when reviewing studies subject to Subpart C*

25-MAR-2021

Board E (Effective 2021-03-01)

Members; Quorum of 4; 5 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
More, Frederick (Chair)	DDS	S	Dentistry	Y	Donnino,Goddard, Hazen, Katz, Nishawala, Novik, Trinh
Katz, Stuart (Vice-Chair)	MD	S	Cardiology	Y	Vice Chair Alternates: Donnino, Hazen, More, Nishawala, Novik Member Alternates: Donnino, Kerwin
Basu Roy, Upal	PhD, MPH	S	Community Representative	N	Bee, Laury, Raskin, Wu(Lillian)
Gallagher, Richard	PhD	S	Child & Adolescent Psychiatry	Y	Barr, Bartlett, Chervinsky, Fieremans ,Gonen, Storey
Goddard, David H	MD	S	Rheumatology	Y	Aggarwal, Berk, Bogenschutz, Brar, Davies, Deifenbach, Donnino, Du, Frankle, Hazen, Kim, Kirsch, Kwa, Lamont, Lewis, Moskovits, Nishawala, Nolan, Novik, Ramirez, Ross, Ross-Rizzo, Rotrosen, Ryan, Saint Fleur, Schiff, Tunik, Wang, Wu

Johnson, Nadia	MS	S	IRB Administration	Y	Berkovitz, Godina, Jeschke-Lopez
Kadidal, Shane *	JD	NS	Law-Prisoner Advocate	N	Brown
Panageas, Helen	BA	NS	IRB Administration	Y	Dvorkin, Liu, Mann, Maril, McGowan, Pogorelec-Khan, Redmond, Vieira

**Counts toward quorum only when reviewing studies subject to Subpart C*

25-MAR-2021

Board F (Effective 2021-03-01)

FWA# 00000726

Members; Quorum of 8; 8 for prisoner-related studies

Member	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate(s)
Goddard, David (Chair)	MD	S	Rheumatology	MD	Donnino, Hazen, Katz, More, Nishawala, Novik, Trinh
Marciano, Tuvia (Vice Chair)	MD	S	GI/ Pediatrics	Y	Donnino, Hazen, Nishawala,
Bee, Peter	JD	NS	Community Representative	N	Basu Roy, Laury, Raskin, Wu(Lillian)
Brown, Justin *	M	NS	Prisoner Advocate	N	Kadidal, Shane
Cataletto, Mary	MD & MMM	S	Pulmonary/Pediatrics	Y	Nolan, Ramirez
Dutka, Paula	BSN, MSN	S	Nephrology – Nursing Representative	Y	Godina
Garrison, Michael	MD	S	Oncology	Y	Davies, Diefenbach, Du, Kwa, Moskovits, Novik, O'Keeffe, Ryan, Saint Fleur, Schiff, Wu
Islam, Shahidul	DrPH, PStat®	S	Biostatistics	Y	Akerman, Meredith

Kerwin, Todd	MD	S	Cardiology	Y	Donnino, Katz
Kuokkanen, Satu	MD, PhD	S	OB/GYN	Y	Mehta-Lee, Wissner-Greene
Nicolas, Barnaby	MSIS, AHIP	NS	Non-Scientist	Y	
Petrone, Patrizio	MD	S	Surgery	Y	Hazen
Redmond, Diane	CIM	NS	IRB Administration	Y	Mann, Maril, Panageas, Pogorelec-Khan
Saenger, Paul	MD	S	Pediatrics Endocrinology	Y	Brar, Ramirez
Vasile, Alicia	RPh	S	Pharmacy	Y	Bliss, Dubrovskaya, Wong

Counts toward quorum only when reviewing studies subject to Subpart C

Alternates

Alternate	Degree(s)	Science – Non-Science	Specialty	Affiliated With NYU	Alternate For
Aggarwal, Vinay	MD	S	Orthopedic Surgery	Y	Kirsch, Lamont , **Board E only Goddard**
Akerman, Meredith	MD	S	Biostatistics	Y	Islam
Barr, William	PhD	S	Neuropsychology	Y	Berk, Chevinsky, Frankle, Gallagher, Nishawala, Ross
Bartlett, Rachel	PhD	S	Radiology	Y	Gonen, Storey, **Board E only Gallagher**
Basu Roy, Upal	PhD, MPH	S	Community Representative	Y	Raskin, Wu (Lillian)
Bee, Peter	JD	NS	Community Representative	N	Basu Roy, Laury, Raskin, Wu (Lillian)
Berk, Thomas	MD	S	Neurology	Y	Barr, **Board E only Goddard**
Berkovitz, David	MD	S	IRB Administration	Y	Godina
Bliss, Samuel	PharmD	S	Pharmacy	Y	Dubrovskaya, Vasile, Wong
Bogenschutz, Michael	MD	S	Psychiatry	Y	Barr, Chervinsky, Frankle, Gallagher, Nishawala, Ross, **, Board E only Goddard**
Brar, Preneet	MD	S	Pediatric Endocrinology	Y	Ramirez, Saenger **, Board E only Goddard**
Brown, Justin	MHA	NS	Prisoner Advocate	N	Kadidal
Cataletto, Mary	MD, MMM	S	Pulmonary/Pediatrics	Y	Nolan
Chervinsky, Alexander	PhD	S	Neuropsychology	Y	Barr, Bogenschutz, Gallagher, Nishawala, Ross
Davies, Faith	MD	S	Oncology	Y	Du, Garrison, Kwa, Saint Fleur, Schiff, Wu, **, Board E only Goddard**

Diefenbach, Catherine	MD	S	Oncology	Y	Du, Garrison, Kwa, Saint Fleur, Schiff, Wu, **, Board E only Goddard**
Donnino, Robert	MD	S	Medicine – Cardiology	Y	Hazen, Katz, More, Nishawala, Novik, Trinh , , **Board E only Goddard**
Du, Kevin	MD, PhD	S	Radiation Oncology	Y	Davies, Diefenbach, Garrison, Kwa, Saint Fleur, Schiff, Wu, **Board E only Goddard**
Dubrovskaya, Yanina	PharmD	S	Pharmacy	Y	Bliss, Wong
Dvorkin, Ella		NS	IRB Administration	Y	Panageas
Fieremans, Els	PhD	S	Radiology	Y	Bartlett, Gonen, Storey **Board E only Gallagher**
Frankle, William Gordon	MD	S	Psychiatry	Y	Barr, Bogenschutz, Gallagher, Nishawala, Ross **, Board E only Goddard**
Gallagher, Richard	PhD	S	Child & Adolescent Psychiatry	Y	Chervinsky, Frankle, Nishawala, Ross
Goddard, David	MD	S	Rheumatology	Y	Katz, More, Novik, Trinh
Gonen, Oded	PhD	S	Radiology	Y	Bartlett, Storey, **Board E only Gallagher**
Garrison, Michael	MD	S	Oncology/Hemtology	Y	Davies, Diefenbach, Du, Kwa, Saint Fleur, Schiff, Wu
Hazen, Alexes	MD	S	Plastic Surgery	Y	Katz, More, Nishawala, Novik, Trinh **, Board E only Goddard**
Jeschke-Lopez, Ikoa	MD	S	IRB Administration	Y	Godina
Johnson, Nadia	MS	S	IRB Administration	Y	Godina
Katz, Stuart	MD	S	Cardiology	Y	Donnino, Hazen, More, Nishawala, Novik, Trinh **, Board E only Goddard**
Kerwin, Todd	MD	S	Cardiology	Y	Donnino
Kim, Sunmi	MD	S	Anesthesiology	Y	Wang**, Board E only Goddard**
Kirsch, Thorsten	MD	S	Orthopedic Surgery	Y	Aggarwal, Lamont**, Board E only Goddard**
Kuokkanen, Satu	MD, PhD	S	OB/GYN	Y	Mehta-Lee
Kwa, Maryann	MD	S	Oncology	Y	Davies, Diefenbach, Du, Garrison, Saint Fleur, Schiff, Wu**, Board E only Goddard**
Lamont, Justin	MD	S	Orthopedic Surgery	Y	Aggarwal, Hazen, Kirsch**, Board E only Goddard**
Laury, Sarah	BA	NS	Community Representative	Y	Bee, Raskin, Wu(Lillian)
Liu, Jasmine	BS	NS	IRB Administration	Y	Panageas
Lewis, Ariane	MD	S	Neurocritical Care	Y	Barr, Berk**, Board E only Goddard**
Mann, Erik	MPH	NS	IRB Administration	Y	Panageas
Maril, Robert	BM, MM	NS	IRB Administration	Y	Panageas
McGowan, Richard	MLS	NS	Public Services	Y	Panageas, Vieira
More, Frederick	DDS	S	Dentistry – Pediatric	Y	Hazen, Katz, Nishawala, Novik, Trinh
Moskovits, Tibor	MD	S	Hematology – Oncology	Y	Diefenbach, Du, Garrison, Kwa, Saint Fleur, Schiff, Wu **, Board E only Goddard**
Nishawala, Melissa	MD	S	Child & Adolescent Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Donnino, Frankle, Hazen, Katz, More, Novik, Ross, Trinh**, Board E only Goddard**

Nolan, Anna	MD	S	Pulmonary	Y	**Board E only Goddard**
Novik, Yelena	MD	S	Oncology	Y	Davies, Diefenbach, Du, Katz, Kwa, Hazen, More, Nishawala, Saint Fleur, Trinh, Wu**, Board E only Goddard**
O'Keeffe, Mary	MD	S	Oncology/Hemtology	Y	Davies, Diefenbach, Du, Garrison, Kwa, Saint Fleur, Schiff, Wu
Oshva, Lillian	MD	S	Emergency Medicine	Y	Ramirez**, Board E only Goddard**
Petrone, Patrizio	MD	S	Surgery	Y	Aggarwal, Hazen
Pogorelec-Kahn, Dana	BA	NS	IRB Administration	Y	Panageas
Ramirez, Michelle	MD	S	Pediatric Critical Care	Y	Brar**, Board E only Goddard**
Raskin, Joyce	JD	NS	Community Representative	N	Basu Roy, Laury, Wu
Redmond, Diane	CIM	NS	IRB Administration	Y	Panageas
Ross, Stephen	MD	S	Addiction Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Nishawala**, Board E only Goddard**
Ross-Rizzo, John	MD	S	Neurology	Y	Barr, Chervinsky, **Board E only Goddard**
Rotrosen, John	MD	S	Psychiatry	Y	Barr, Bogenschutz, Chervinsky, Frankle, Gallagher, Nishawala, Ross**, Board E only Goddard**
Ryan, Theresa	MD	S	Oncology	Y	Davies, Diefenbach, Du, Garrison, Kwa, Saint Fleur, Schiff, Wu**, Board E only Goddard**
Saint Fleur, Shella	MD	S	Hematology – Oncology	Y	Davies, Diefenbach, Du, Kwa, Schiff, Wu**, Board E only Goddard**
Saenger, Paul	MD	S	Pediatric Endocrinology	Y	Brar
Schiff, Peter	MD	S	Radiation – Oncology	Y	Davies, Diefenbach, Du, Garrison,Kwa, Saint Fleur**, Board E only Goddard**
Storey, Elizabeth	PhD	S	Radiation	Y	Bartlett, Gonen, **Board E only Gallagher**
Trinh, Chau	DrPH	S	Population Health	Y	Katz, More, Novik
Tunik, Michael	MD	S	Pediatric EM	Y	Brar, More, Ramirez**, Board E only Goddard**
Vasile	RPh	S	Pharmacy	Y	Bliss, Dubrovskaya, Wong
Vieira, Dorice	MA	NS	Public Services	Y	McGowan, Panageas
Wang, Jing	MD	S	Anesthesiology	Y	Kim**, Board E only Goddard**
Wissner-Greene	MD, MA	S	Medicine – Endocrinology – Ob-Gyn	Y	Mehta-Lee
Wong, Doris	PharmD	S	Pharmacy	Y	Bliss, Dubrovskaya, Vasile
Wu, Jennifer	MD	S	Oncology	Y	Davies, Diefenbach, Du, Garrison, Kwa, Saint Fleur**, Board E only Goddard**
Wu, Lillian	BA, MA	NS	Community Representative	N	Basu Roy, Bee, Laury, Raskin

25-MAR-2021